Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844505 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 945
- Enrollment target
NCT01844505 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 945 participants.
The verdict
NCT01844505, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 945 participants
- Enrollment target
Study Summary
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Placebo for Nivolumab
- BIOLOGICAL Placebo for Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 945 participants |
| Start Date | 2013-06-11 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01844505
The ClinicalTrials.gov registry entry for NCT01844505 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 945 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT01844505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01844505 about?
NCT01844505 is a clinical study titled "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)". The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
What is the current status of trial NCT01844505?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 945 participants. The study started on 2013-06-11. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT01844505?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Placebo for Nivolumab (BIOLOGICAL), Placebo for Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01844505?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.